Nobel İlaç Restructures Organization in Line with Growth Targets
Nobel İlaç has restructured its Sales and Marketing organization in line with its growth targets. As part of this restructuring, new appointments were made to the Primary Products and Specialty Products directorates, while Special Products and Longevity directorates, focused on future healthcare needs, were added to the organizational structure. By entrusting four critical leadership positions to executives who rose through its own ranks, the company reinforced its approach of carrying its institutional memory and leadership culture into the future.
Nobel Pharmaceuticals has restructured its Sales and Marketing organization in line with its growth targets. As part of this process, new appointments were made to the directorates of Core Products and Specialty Products, while Special Products and Longevity directorates focused on addressing future health needs were also integrated into the organizational structure. The company has entrusted four critical leadership positions to managers developed within its own ranks, strengthening its approach to carrying institutional memory and leadership culture into the future.
Nobel Pharmaceuticals, with its roots in pharmacy and over 70 years of experience, today operates as Turkey's pharmaceutical company with the widest international organization. In line with its domestic growth strategy, the company has restructured its Sales and Marketing organization. Sales and marketing activities previously conducted under two separate directorates domestically have now been consolidated under four main directorates: Core Products, Specialty Products, Special Products, and Longevity.
Under the new organizational structure, Bahri Karayaka, Head of Cardiology 2 Division, became Director of Core Products; Ali Engin, Head of Cardiology 1 Division, became Director of Specialty Products; Kemal Özkan, Head of Hepatology, Nephrology and Rare Diseases 2 Division, became Director of Special Products; and Özer Sinan Yalanuz, Head of Nobel Longevity Division, became Director of Nobel Longevity.
Additionally, Duygu Değirmenci was appointed to the Central Nervous System Marketing Management position.
With the new structure, Nobel Pharmaceuticals aims to strengthen its position with its current portfolio while enabling continued growth in new areas that will address future health needs.
The appointment of managers who have spent much of their careers within Nobel Pharmaceuticals and have held significant responsibilities in various areas of the company to their new positions is seen as a reflection of Nobel's approach to developing its own leaders.
Gallery
